Effect of tongguan capsule on coagulant and fibrinolysis system in patients with coronary heart disease after percutaneous coronary intervention.
- Author:
Xiang-Wei ZHANG
1
;
Min-Zhou ZHANG
Author Information
- Publication Type:Clinical Trial
- MeSH: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antithrombin III; analysis; Capsules; Coronary Disease; blood; drug therapy; therapy; Drugs, Chinese Herbal; therapeutic use; Female; Fibrinolysis; Humans; Male; Middle Aged; Phytotherapy; Plasminogen Activator Inhibitor 1; blood; Prospective Studies; Stents; Tissue Plasminogen Activator; blood; von Willebrand Factor; analysis
- From: Chinese Journal of Integrated Traditional and Western Medicine 2004;24(12):1065-1068
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the effect and mechanism of Tongguan capsule (TGC) on coagulant and fibrinolysis system in patients with coronary heart disease (CHD) after percutaneous coronary intervention (PCI).
METHODSAdopting the prospective, randomized controlled method to observe the coagulant-fibrinolysis related indexes, including tissue plasminogen activator (t-PA), plasminogen activator inhibitor 1 (PAI-1), von Willebrand factor (vWF), antithrombin II (AT-III) and fibrinogen (FIB), in CHD patients after PCI, there were 26 patients in the treated group treated by TGC with Western medicine and 26 in the control group treated by Western medicine alone.
RESULTSAfter treatment, all the indexes were improved in both groups (P < 0.05). As comparison between the two groups, AT-III and t-PA were higher in the treated group than those in the control group; PAI-1 levels showed insignificant difference at 1 month after treatment, but at 3 months after treatment, it was significantly lower in the treated group (P < 0.05); vWF showed no significant difference either at 1 or at 3 months after treatment; and FIB was lower in the treated group both at 1 and 3 months after treatment (P < 0.01).
CONCLUSIONTGC could improve the hypercoagulant status and adjust the balance between coagulant-fibrinolysis system of CHD patients after PCI by increasing AT-III and t-PA levels, and lowering FIB and PAI-1 levels in the body.
